These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Off-label dermatologic uses of anti-TNF-a therapies. Alexis AF; Strober BE J Cutan Med Surg; 2005 Dec; 9(6):296-302. PubMed ID: 16699906 [TBL] [Abstract][Full Text] [Related]
9. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Joyau C; Veyrac G; Dixneuf V; Jolliet P Clin Exp Rheumatol; 2012; 30(5):700-6. PubMed ID: 22935567 [TBL] [Abstract][Full Text] [Related]
10. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review. Fidder HH; Singendonk MM; van der Have M; Oldenburg B; van Oijen MG World J Gastroenterol; 2013 Jul; 19(27):4344-50. PubMed ID: 23885145 [TBL] [Abstract][Full Text] [Related]
11. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α. Ueda N; Tsukamoto H; Mitoma H; Ayano M; Tanaka A; Ohta S; Inoue Y; Arinobu Y; Niiro H; Akashi K; Horiuchi T Inflamm Bowel Dis; 2013 May; 19(6):1224-31. PubMed ID: 23619715 [TBL] [Abstract][Full Text] [Related]
12. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658 [TBL] [Abstract][Full Text] [Related]
13. [Autoimmune aspects of treatment with TNF-alpha inhibitors]. Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135 [TBL] [Abstract][Full Text] [Related]
14. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908 [TBL] [Abstract][Full Text] [Related]
15. The Use of TNF-α Inhibitors in Active Ankylosing Spondylitis Treatment. Zouris G; Evangelopoulos DS; Benetos IS; Vlamis J Cureus; 2024 Jun; 16(6):e61500. PubMed ID: 38952586 [TBL] [Abstract][Full Text] [Related]
16. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. Murdaca G; Colombo BM; Puppo F Drugs Today (Barc); 2011 Apr; 47(4):277-88. PubMed ID: 21573251 [TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Behm BW; Bickston SJ Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120 [TBL] [Abstract][Full Text] [Related]
18. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. Bourne T; Fossati G; Nesbitt A BioDrugs; 2008; 22(5):331-7. PubMed ID: 18778114 [TBL] [Abstract][Full Text] [Related]
19. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors. Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418 [TBL] [Abstract][Full Text] [Related]
20. TNF inhibition for ophthalmic indications: current status and outlook. Rifkin LM; Birnbaum AD; Goldstein DA BioDrugs; 2013 Aug; 27(4):347-57. PubMed ID: 23568177 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]